Titanium Platelet-rich Fibrin in Sinus Floor Elevation Through Flapless Transcrestal Approach

Evaluation of the Use of Titanium Platelet-rich Fibrin in Sinus Floor Elevation Through Flapless Transcrestal Approach ( a Randomized Controlled Clinical Trial)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05721612

Enrollment

Registered

2023-02-10

Start date

2022-03-15

Completion date

2023-02-05

Last updated

2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sinus Floor Elevation

Brief summary

Dental implant therapy in the posterior maxilla may be difficult owing to limited bone height after dental extraction with sinus pneumatization. Several approaches for sinus floor elevation have been documented, and hence flapless transcrestal sinus floor elevation is minimally invasive technique which is used in moderately defected maxilla. Aim of the study: to evaluate both clinical and radiographic outcomes in sinus floor elevation following dental implant placement using flapless transcrestal sinus lift approach with Titanium platelet rich fibrin (TPRF) as a sole sinus graft material compared to Platelet rich fibrin (PRF).

Interventions

OTHERFlapless transcrestal sinus lift approach with TPRF

Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.

OTHERFlapless transcrestal sinus lift approach with PRF

Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patient seeking replacement of a missed maxillary posterior teeth by a delayed dental implant procedure. * Residual bone height is (4-7) mm measured from crestal bone to sinus floor. * Good oral hygiene

Exclusion criteria

* Uncontrolled Diabetes. * Coagulation disorders. * Immunological disorders. * Previous radiation of the head and neck region. * Abnormal bone physiology. * Therapy with Bisphosphonates.

Design outcomes

Primary

Measure	Time frame	Description
Change in bone density	Baseline and 6 months	Cuts of CBCT (cross sectional, axial and sagittal view), bone density, will be analyzed using On-demand software. The radiographic evaluation will be based on radiological parameters, using reference points and lines at T0 and T1.

Secondary

Measure	Time frame	Description
Change in implant stability	Baseline and 6 months	Secondary implant stability will be measured 6 months post-operatively using Osstell device.
change in pain scores	1st day, 3rd day and 1 week	Pain (by Visual Analogous Scale) ranges from 0 to 10 0 - No pain. 2 to 4 - Mild pain. 5 to 7 - Moderate pain. 8 to 10 - severe pain.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026